News | May 7, 2019

Corindus Equips The World's First Fully Robotic Catheterization Laboratory

WALTHAM, MASS.--(BUSINESS WIRE)--

Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Vascular Robotic Systems, making it the first hospital in the world to adopt vascular robotic systems in all vascular intervention treatment rooms. The outfitted labs will allow physicians to leverage the latest robotic technology for percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) and provide all patients requiring these procedures at Chesapeake Regional access to the latest technology in cardiovascular disease care.

“Through a full commitment to our technology, Chesapeake Regional Medical Center has positioned itself as a premier vascular treatment facility in the U.S.,” said Mark Toland, President and Chief Executive Officer of Corindus. “Just a few months after their first CorPath GRX purchase, strong physician demand led to the purchase of a second system, offering all of their patients suffering from heart disease the option of robotic treatment. In addition, more physicians are opting to treat their patients at Chesapeake Regional to provide them with the benefits of robotics and the most advanced treatment options available. We want to congratulate Chesapeake Regional on this landmark achievement and for embracing robotic-assisted procedures to enhance patient care,” added Toland.

The multi-system installation addresses the needs and demands of the physicians, staff, and patients. The center is the first non-academic hospital in the state of Virginia to launch a vascular robotic program and perform a robotic-assisted PCI procedure using the CorPath GRX System, and is the first facility in the world with vascular robotic capabilities in all catheterization labs. Ronald McKechnie, MD, Medical Director of the Catheterization Lab at Chesapeake Regional Medical Center, performed the organization’s first robotic-assisted PCI procedure on March 18, 2019.

“Since installing our first system, we have taken pride in providing our patients with access to the most advanced treatment options, while also providing our physicians and staff protection from the daily occupational hazards involved with vascular intervention,” said Dr. McKechnie. “Technological advances like these will not only improve outcomes for our patients, but also change the landscape for the future treatment of cardiovascular disease everywhere. Patients are seeking robotic technology for coronary care and we are thrilled to be a part of this movement.”

To learn more about Corindus and CorPath GRX, please visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.

About Chesapeake Regional Healthcare

Chesapeake Regional Healthcare is home to Chesapeake Regional Medical Center, the only independent, community-based hospital in the Hampton Roads region providing technologically advanced health care to the residents of southeastern Virginia and northeastern North Carolina for more than 40 years. It offers a nationally accredited Chest Pain Center, a Bariatric Surgery Center of Excellence, several five-star ratings from Healthgrades® and one of the busiest Emergency Departments and maternity wards in the area. With more than 600 physicians on staff, the first da Vinci® XI Surgical System in the state of Virginia and the first hospital in the world to adopt CorPath GRX Vascular Robotic Systems in all vascular intervention treatment rooms, Chesapeake Regional is dedicated to putting patients first with the most advanced treatments in health care and a personalized touch. For more information, visit www.chesapeakeregional.com.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements regarding or such as:

  • More physicians are opting to treat their patients at Chesapeake Regional to provide them with the benefits of robotics and the most advanced treatment options available.
  • Technological advances like these will not only improve outcomes for our patients, but also change the landscape for the future treatment of cardiovascular disease everywhere.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: our ability to expand our technology platform and achieve the advances necessary for telestenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries, including for stroke and other neurovascular interventions; the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.


Copyright Business Wire 2019